MindMaze Therapeutics Advances At-Home Reimbursement in Europe

MindMaze Therapeutics Holding SA has enrolled the first patients in the SwissNeuroRehab study, marking progress in its strategy to secure at-home reimbursement in Europe. As part of a broader effort, the company has also initiated the REACT-AVC study in France. These studies aim to extend patient care from hospitals to home, reinforcing MindMaze's presence in key European markets.

The SwissNeuroRehab study, backed by Innosuisse, involves major Swiss centers and evaluates the sustainability of delivering intensive neurorehabilitation within a continuity-of-care framework. The study targets extended patient engagement across various rehabilitation phases, crucial for building an at-home care reimbursement framework.

In France, the REACT-AVC study focuses on early outpatient and home-based stroke rehabilitation. Together, these studies support MindMaze’s ambition to implement its reimbursement strategy across Europe, following a successful U.S. model featuring established CPT reimbursement codes.